Cabaletta Bio Inc (CABA) concluded trading on Thursday at a closing price of $1.81, with 9.39 million shares of worth about $17.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.42% during that period and on May 15, 2025 the price saw a gain of about 39.23%. Currently the company’s common shares owned by public are about 50.74M shares, out of which, 45.71M shares are available for trading.
Stock saw a price change of 49.59% in past 5 days and over the past one month there was a price change of 61.61%. Year-to-date (YTD), CABA shares are showing a performance of -20.26% which decreased to -83.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.99 but also hit the highest price of $13.50 during that period. The average intraday trading volume for Cabaletta Bio Inc shares is 933.48K. The stock is currently trading 41.19% above its 20-day simple moving average (SMA20), while that difference is up 28.60% for SMA50 and it goes to -40.96% lower than SMA200.
Cabaletta Bio Inc (NASDAQ: CABA) currently have 50.74M outstanding shares and institutions hold larger chunk of about 68.57% of that.
The stock has a current market capitalization of $91.85M and its 3Y-monthly beta is at 2.65. It has posted earnings per share of -$2.34 in the same period. It has Quick Ratio of 6.15 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CABA, volatility over the week remained 12.66% while standing at 9.72% over the month.
Stock’s fiscal year EPS is expected to drop by -0.84% while it is estimated to increase by 9.07% in next year. EPS is likely to grow at an annualized rate of 5.64% for next 5-years, compared to annual growth of -20.35% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on December 20, 2024 offering an In-line rating for the stock and assigned a target price range of between $15 and $6 to it. Coverage by Wells Fargo stated Cabaletta Bio Inc (CABA) stock as an Equal weight in their note to investors on December 19, 2024, suggesting a price target of $6 for the stock. On October 10, 2024, UBS Initiated their recommendations, while on February 05, 2024, Jefferies Initiated their ratings for the stock with a price target of $36. Stock get an Outperform rating from William Blair on November 29, 2023.
